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The involvement of insulin, the insulin-like growth factors (IGF1, IGF2) and their receptors in
central nervous system development and function has been the focus of scientiﬁc interest for more
than 30 years. The insulin-like peptides, both locally-produced proteins as well as those transported
from the circulation into the brain via the blood–brain barrier, are involved in a myriad of biological
activities. These actions include, among others, neuronal survival, neurogenes, angiogenesis,
excitatory and inhibitory neurotransmission, regulation of food intake, and cognition. In recent
years, a linkage between brain insulin/IGF1 and certain neuropathologies has been identiﬁed.
Epidemiological studies have demonstrated a correlation between diabetes (mainly type 2) and
Alzheimer's disease. In addition, an aberrant decline in IGF1 values was suggested to play a role in
the development of Alzheimer's disease. The present review focuses on the expression and function
of insulin, IGFs and their receptors in the brain in physiological and pathological conditions.
& 2014 Elsevier B.V. and ECNP. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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receptors in the brain.
Expression of insulin-like peptides in brain
The IR is expressed in speciﬁc brain areas (e.g., olfactory
regions, amygdaloid complex, hippocampus, pyriform
cortex, thalamus, etc.).
Insulin mRNA is expressed in certain brain nuclei (mainly
during development).
Insulin and IGF-1 enter the brain via the BBB.1. Introduction: the insulin-IGF system
The insulin-like growth factor (IGF) system constitutes a
hormonal network comprising ligands, receptors and binding
proteins. The ligands, insulin, IGF-1 and IGF-2 (herein
named IGF-related peptides), have distinct tissues of
expression and separate physiological functions. They gen-
erally activate different receptors, though both the insulin
receptor (IR) and the Type 1 IGF receptor (IGF-1R), despite
major differences in expression patterns, are very similar in
both structure and activity in regard to signaling pathways.
Insulin is primarily a metabolic hormone functioning on
muscle, fat and liver via activation of its cognate receptor,
though it also functions on tissues that are not considered
classically metabolic, such as the vasculature and the brain.
The IGFs have a more mitogenic role both during fetal
development and postnatally. The IGFs are important
progression factors during the cell cycle and they affect
cell survival in adult tissues. In certain cases, IGF-1 and IGF-
2 actually demonstrate speciﬁc differentiated functions via
activation of the IGF-1R, as the IGF-2R does not have
signaling capabilities. The IGF-binding proteins (IGFBP1-6)
have high afﬁnity for both IGF-1 and IGF-2, protect the IGFs
in the circulation and deliver them to the tissues. Hence,
IGFBPs' main role is to modulate the bioavailability of the
ligands. The IGFBPs exhibit numerous biological functions,
both via their control of local “free” (unbound) IGFs'
interactions with cell-surface receptors and, in some cases,
in a ligand-independent manner. As opposed to the IGFs,
insulin has no similar binding proteins and circulates freely.
In this review we will discuss the expression and function of
insulin, IGFs and their receptors in the brain. For clarity we
will describe insulin and the IGFs separately.IGF-1 and IGF1-R are widely expressed in brain.
Bioactivities of insulin-like peptides in brain
Neuronal survival.
Excitatory and inhibitory neurotransmission.
Suppress food intake.
Maintain normal free fatty acid levels.
Improve cognition.
Protection against cellular injury.
Neurogenesis, angiogenesis and amyloid clearance.2. Insulin and the brain
2.1. Insulin receptor expression in the brain
The IR is widely expressed in the brain but demonstrates denser
expression in certain regions (Unger et al., 1991). A higher
level of expression is found in the olfactory regions, amyg-
daloid complex, hippocampus, pyriform cortex and thalamus.Importantly, the IR is also highly expressed in the hypothalamus,
speciﬁcally in the arcuate, supraoptic and dorsomedial nuclei
(Havrankova et al., 1978; Unger et al., 1989; Wozniak et al.,
1993). The question whether insulin itself is expressed in the
brain has been the topic of controversial debate for many
years. There is signiﬁcant evidence that insulin mRNA is present
in certain regions of the brain during development as well as in
adult brain (Devaskar et al., 1993). Peripheral insulin enters the
brain via a saturable mechanism involving the blood–brain-
barrier (BBB), and it seems that the rate of entry varies
according to the region. The olfactory bulb, which as men-
tioned above has the highest level of IR in the brain
(Havrankova et al., 1978; Gupta et al., 1992), tends to have
the faster rate of transport (Banks et al., 2012). Indeed, this
region is being used to transport insulin into the brain for
therapeutic purposes. Table 1 summarizes the sites and
mechanisms of expression of insulin-like peptides and receptors
in brain as well as some of their biological activities.
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Classically, IR signaling involves the PI3K kinase/Akt and
MAPK kinase pathways, leading to glucose transport in
adipocytes by the former pathway and other effects through
the MTOR/S6K kinase pathways that affect translation and
even gene expression. In addition, there are so-called “non-
canonical” IR signaling pathways involving, for example, the
protein kinase-C (PKC)/NF-κB pathway. In this context,
insulin was shown to regulate p-glycoprotein in rat brain
microvessel endothethial cells via the PKC/NF-κB cascade
and not necessarily through the PI3/Akt pathway (Liu et al.,
2009). An important function for insulin in the central
nervous system (CNS) appears to be neuronal survival
(Mielke et al., 2006). When rat hippocampal cells in culture
are stressed by oxygen or glucose deprivation their survival
can be rescued by insulin signaling through the IR. Insulin
also protects embryonic retinal cells during development
from caspase and cathepsin-mediated apoptosis by inhibit-
ing the expression of these pro-apoptotic proteins (Díaz
et al., 1999).
There are numerous studies that have demonstrated that
IR signaling plays a role in both excitatory and inhibitory
neurotransmission, functions that are involved in high
neuronal functions. In addition, short- and long-term mem-
ory may affect IR expression levels in the rat hippocampus,
while the expression levels of other neurotransmitter
receptors, such as the NMDA and AMPA receptors, remain
unchanged (Plum et al., 2005). Further support for a role of
insulin in neuronal modulation was provided by studies
showing that intranasal insulin delivery in mice led to an
increased expression of the potassium ion channel Kv1.3 in
the olfactory bulb (Marks et al., 2009). Mice that received
intranasal insulin have improved cognition, as shown by
short- and long-term object recognition. These ﬁndings
suggest that insulin delivered to the CNS increases neuronal
activity and improves memory by mechanisms involving
changes in Kv1.3 levels.2.3. Central actions of insulin on peripheral
glucose and lipid metabolism and appetite are
mediated at the hypothalamic level
Insulin, when applied to the CNS, has been shown to suppress
food intake via signaling in the hypothalamus (Scherer and
Buettner, 2011). Indeed, intranasal administration of insulin
in men decreased food intake after short-term treatment
while weight reduction was achieved after long-term treat-
ment (Hallschmid et al., 2012). Furthermore, neuroimaging
studies have also demonstrated a similar effect in women,
although women show a reduced sensitivity to this form of
therapy. While most evidence supports the notion that the
effect on food intake reduction is the result of direct insulin
action on the hypothalamus, other studies suggest effects on
extra hypothalamic regions that regulate the reward compo-
nent of satiety (Hallschmid et al., 2012).
With regard to fat, activation of brain IRs and, to some
degree, peripheral IRs, maintain normal circulating free
fatty acids levels by suppressing lipolysis and inducing
lipogenesis in white adipose tissue (WAT). The central effect
of brain insulin on WAT is via reduction of sympatheticnervous system outﬂow to WAT and is apparently separate
from its effect on appetite. Infusion of insulin into the brain
suppresses hepatic gluconeogenesis without affecting gly-
cogenolysis (Obici et al., 2002; Gutierrez-Juarez et al.,
2004). Many of the functions described here are mediated
by insulin's interaction with the Agouti-related peptide
(AgRP) and pro-opiomelanocortin (POMC) neurons in the
hypothalamus, though other CNS IRs might also be involved.
3. Insulin-like growth factors and the brain
IGF-1 and the IGF-1R are expressed in close proximity to each
other in the various brain regions, suggesting a paracrine or
autocrine functional loop (Bondy et al., 1992). IGF-1 is
expressed in the rodent embryo, peaking in the second week
post-natally but continues to be expressed in the adult brain
(Bondy et al., 1990) and, in particular, in neuronal cells
(Shemer et al., 1987). IGF-2, on the other hand, is expressed
mostly in mesenchymal tissues, mainly the meninges and
choroid plexus (20). The last structure is the main source of
cerebrospinal ﬂuid (CSF) IGF-2. Similarly, while the IGF-1R is
widely expressed it also demonstrates a degree of regional
distribution, with high levels of expression detected in the
developing cerebellum, midbrain, olfactory bulb and in the
ventral ﬂoorplate of the hindbrain (Bondy et al., 1992). The
level of IGF-1R expression decreases to adult levels soon after
birth but remains relatively high in the choroid plexus,
meninges, and vascular sheaths (Russo et al., 2005).
3.1. The two sources of IGF peptides in the brain
The IGF-related peptides may affect brain function by
either local tissue expression or by peripheral circulating
peptides crossing the BBB. BBB uptake of circulating IGFs
involves the IGF-1R and the low-density lipoprotein
receptor-related protein 1 (LRP1), thus IGFs can reach the
CSF as well as the hypothalamus and hippocampus. Other
regions of the brain are then reached via speciﬁc transport
mechanisms. On the other hand, experimental evidence
suggests the production of the IGF-related peptides includ-
ing insulin in certain regions of the brain. Thus, both local
production and peptides derived from the peripheral circu-
lation may play a role in regulation of brain function.
3.2. Circulating IGF-1 and central effects
In addition to its neurotrophic effects, circulating IGF-1 also
demonstrates effects on cognition. Similar to humans with
reduced serum IGF-1 levels and associated cognitive dys-
function (see below), animal models also demonstrate a
correlation between endocrine IGF-1 levels and brain-
related functions. These cognitive declines were reversible
by prolonged systemic administration of IGF-1. These results
suggest that the neurotrophic actions of IGF-1 affect
glutamatergic synapses within the hippocampal circuitries
thereby affecting learning and memory. Other effects of
IGF-1 on brain cells include protection against cellular
injury, neurogenesis, angiogenesis and even amyloid clear-
ance (Aberg et al., 2000; Carro et al., 2000; Lopez-Lopez
et al., 2004; Trejo et al., 2007).
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Similar to IGF-1, IGF-2 also plays a role in memory enhance-
ment (Alberini and Chen, 2012). While the IGF-2R demon-
strates the highest afﬁnity for IGF-2, it has no intrinsic
signaling function and thus IGF-2 effects are mostly
mediated via the IGF-1R and/or the IR. IGF-2 mRNA and
protein expression is increased in hippocampal regions after
inhibitory avoidance training in rodents. Furthermore, anti-
sense mediated reductions in IGF-2 in the dorsal hippocam-
pus inhibit the long-term inhibitory avoidance memory
consolidation. Similar results were obtained using an IGF-2
inhibitory antibody administered centrally (Chen et al.,
2011).
3.4. IGFBPs in the brain
Of the six IGFBPs, IGFBP-2, -4 and -5 are more highly
expressed in the brain than the others. As in the peripheral
system, IGFBPs play a regulatory role by binding the IGFs.
In general, gene-deletion and transgenic overexpression of
IGFBPs have affected the brain, mostly commonly via
affecting IGFs effect on brain development. Thus, an
independent effect of IGFBPs has not been demonstrated
(D'Ercole et al., 2002).
4. Lessons from animal models
The roles of the insulin and IGF signaling pathways in the brain
were revealed by analyses of animal models with speciﬁc
disruptions of ligand- or receptor-encoding genes and by
analyses of transgenic mice overexpressing these genes
(Baker et al., 1993). Transgenic animals overexpressing IGF-1
have markedly increased brains and a large number of cellular
components, including neurons and oligodendrocytes.
Disruption of the IGF-1R gene by homologous recombina-
tion results in animals weighing 45% of normal littermates at
the time of birth (Liu et al., 1993). These animals exhibit
generalized developmental abnormalities, including abnor-
mal CNS morphology, hypoplasia, impaired skin and bone
formation, etc. Similar developmental anomalies were seen
in animals with a disruption in the IGF-1 gene, though these
animals weigh about 60% of normal littermates and the
extent of malformations is a bit lower than those seen in
IGF-1R KO animals. In the context of the nervous system,
abnormalities are linked to a reduced population of neuro-
nal cells, defective myelination, and enhanced apoptosis.
5. IGF-1 and brain pathologies
The linkage between the IGF-1 axis and brain pathologies,
particularly Alzheimer's disease (AD), has been the topic of
signiﬁcant interest in recent years. The pathological hall-
mark of AD, the “neuritic” or amyloid plaque, is a dense
conglomerate of amyloid β-peptide (Aβ) ﬁbers and non-
ﬁbrillar forms of Aβ. Neuritic plaques are surrounded by a
number of cellular components, including activated micro-
glia, reactive astrocytes, etc. (Puglielli, 2008). Aβ peptides
are generated by proteolysis of a precursor polypeptide,
termed amyloid precursor protein (APP). APP homeostasis istightly regulated by multiple hormonal and cellular path-
ways, including a series of phosphorylation events (Suzuki
and Nakaya, 2008). A large body of evidence has identiﬁed
IGF-1 as a major regulator of Aβ physiology. Speciﬁcally,
serum IGF-1 controls Aβ clearance from brain via modula-
tion of the levels of carrier proteins transthyretin and
apolipoprotein J, among others (Bates et al., 2009). In
addition, IGF-1 regulates Aβ degradation through its ability
to control insulin degrading enzyme (IDE) availability, an
extracellular protease. Finally, IGF-1 affects cellular uptake
and lysosomal degradation of Aβ via regulation of the
lipoprotein receptor protein family of multicargo transpor-
ter proteins (Torres-Aleman, 2010). The Torres-Aleman
laboratory has also provided evidence that speciﬁc blockage
of the IGF-1R in the rat choroid plexus leads to brain
amyloidosis, cognitive disturbance, and hyperphosphorylated
tau deposits similar to those seen in AD (Carro et al., 2006).
These ﬁndings are consistent with the hypothesis that
aberrant decline in circulating IGF-1 values leads to a
reduction in IGF-1 uptake in brain, with ensuing development
of the Alzheimer's phenotype.
6. Diabetes and brain function
Increasing epidemiological evidence suggests a linkage
between diabetes (particularly type 2 diabetes) and AD
occurrence. In a recent systematic review of the literature
including fourteen studies, a risk ratio greater than one was
reported in all of the studies (median, 1.59; range 1.15–
2.7). In four of these studies, the added risk of AD was
statistically signiﬁcant (median, 1.73; range 1.59–1.9) (Kopf
and Frolich, 2009). Conversely, the incidence of diabetes
and impaired fasting glucose levels was much higher among
AD patients than in age-matched controls, with 81% of the
AD patients exhibiting fasting glucose levels above 110 mg/
dL (Janson et al., 2004). In terms of etiology, both diabetes
and AD constitute degenerative diseases associated with
β-cell destruction and neuronal loss, respectively.
While the biochemical and molecular pathways respon-
sible for the increased risk of developing AD in people with
diabetes remain unclear, a number of putative mechanisms
were postulated that might underlie this association (Yang
and Song, 2013). Some of these pathological processes
include: (i) inﬂammation; (ii) impaired insulin signaling;
and (iii) amyloidogenesis.(i) Inﬂammation: Inﬂammation has been identiﬁed as a
major player in the etiology of obesity, insulin resis-
tance and diabetes (Osborn and Olefsky, 2012). Ele-
vated levels of a wide array of cytokines and immune
mediators can be measured in the circulation as well as
in pancreatic islets of type 2 diabetes patients.
A similar pattern of immune activation is seen in AD,
with elevated values of pro-inﬂammatory proteins and
chemokines detected in post-mortem brains of AD
patients (Akiyama et al., 2000). The role of inﬂammation
as a major driver of AD was suggested by mouse models
showing key functions for a number of chemokines in AD
etiology (Wyss-Coray, 2006).(ii) Impaired insulin signaling: As described above, insulin,
IR and downstream proteins are present in different
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impairment in diabetes and AD could be linked to a
defective IR signaling pathway in the brain (Sato et al.,
2011). Post-mortem analyses of AD brains have shown
reduced levels of insulin, IGFs and receptor mRNAs
compared to control brains. Decreases were also seen
in downstream mediator transcripts and the extent of
these reductions were in correlation with the severity
of the disease (Rivera et al., 2005). An enzyme involved
in pathophysiological activities in both diabetes and AD
is glycogen synthase kinase 3β (GSK3β). GSK3β is a
serine/threonine kinase that is usually constitutively
active and is regulated by insulin-mediated depho-
sphorylation (Kaidanovich and Eldar-Finkelman, 2002).
Mice overexpressing GSK3β in the brain display elevated
concentrations of hyperphosphorylated tau in associa-
tion with a reduction in cognitive parameters. In
contrast, GSK3β abrogation reduced neurodegenera-
tion. Finally, recent studies provided evidence for brain
insulin resistance as a potential etiological factor in AD.
Using an ex-vivo experimental system, Talbot et al.
(2012) showed that the hippocampal formation and, to
a lesser degree, the cerebral cortex in AD cases without
diabetes display diminished response to insulin signal-
ing in the IR-IRS1-PI3K pathway as well as marked
reduction in response to IGF-1 in the IGF-1R-IRS2-
PI3K cascade. Furthermore, these putative biomarkers
of brain insulin resistance increased from normal cases
to mild cognitive impairment to AD cases.(iii) Amyloidogenesis: An additional mechanism associated
with the etiology of both diabetes and AD is amyloido-
genesis. Similarly to the formation of amyloid plaques
composed of insoluble aggregates of Aβ ﬁbers in AD,
islet amyloid deposits are a characteristic feature in
the pancreas of diabetic patients (Yang and Song,
2013). Islet amyloids are composed of aggregates of
amylin, also called human islet amyloid polypeptide
(hIAPP), a 37-amino acid peptide derived from an 89-
amino acid precursor. hIAPP is similar to Aβ ﬁbers on
both structural and morphological parameters (Luca
et al., 2007). Deposition of amyloid in islets leads to a
marked reduction in β-cell mass and function (Clark
et al., 1988).7. Brain IGF-1 receptors and life span
The insulin-IGF-1 signaling pathway plays a key role in the
process of aging. Evidence from several animal models
ranging from D. melanogaster to C. elegans and M. musculus
has clearly established that reduced exposure of tissues to
endocrine or autocrine/paracrine IGF-1 is associated with a
markedly extended lifespan (Yang et al., 2005). While the
mechanisms associated with IGF-1 regulation of lifespan
remain unclear, it has been postulated that longevity is
dictated by a tightly regulated hypothalamic growth
hormone-IGF-1 hormonal axis. The impact of brain IGF-1R
on lifespan has been addressed by speciﬁc inactivation of
the IGF-1R in embryonic mice brain. Partial abrogation of
the receptor inhibited the growth hormone and IGF-1pathways, with ensuing metabolic and developmental
anomalies in postnatal life, including a reduction in adult
size. However, survival curves indicated that impaired IGF-
1R function led to a marked increase in lifespan compared
to controls (914721 compared to 836728 days) (Kappeler
et al., 2008). Of interest, heterozygous brain IGF-1R dis-
ruption had no effect on other brain functions. In this
context, it is important to emphasize the fact that complete
abrogation of brain IGF-1R led to a different phenotype,
associated with increased IGF-1 levels. Hence, IGF-1R gene
dosage has a key role in establishing the hormonal balance
that will shape the ﬁnal phenotype. Finally, genetic altera-
tions in the human IGF-1R gene were identiﬁed in a cohort
of Ashkenazi Jewish centenarians. Linkage between over-
representation of IGF-1R mutations, short stature and
increased serum IGF-1 levels was noticed. These results
highlight the central role of the IGF-1R axis in aging and
indicate that altered IGF-1 signaling may lead to increased
longevity (Suh et al., 2008).8. Potential clinical applications
Scientiﬁc breakthroughs in the area of insulin action in brain
may lead to important translational advances. Given the
brain insulin resistance in AD patients described above,
attenuating this hormonal resistance might constitute a
useful pharmacological intervention (Talbot et al., 2012).
In this context, the use of antidiabetic agents (e.g. metfor-
min) and GLP-1 mimetic agents (e.g. liraglutide) has been
suggested. These drugs cross the BBB, elicit neuroprotective
activities and, importantly, are safe and well-tolerated
medicines. In a pilot study, increasing doses of insulin were
administered intranasally to memory impaired AD patients
or patients with mild cognitive disorder. Cognition was
tested 15 min after insulin administration. Insulin improved
recall on two measures of verbal memory in patients lacking
the ApoE-e4 allele whereas it led to a decline in memory
tasks in patients expressing the ApoE-e4 allele. The ameli-
orative effect of insulin displayed a dose-dependent curve,
with optimal performance observed at 20 I.U. These results
are consistent with the concept that patients with different
genetic backgrounds may respond differently to insulin
therapy (Reger et al., 2008).9. Future directions
The large volume of experimental data collected over the
past 30 years on the role of insulin, IGFs and their receptors
in fundamental biological processes (e.g., development,
brain function, metabolism, etc.), along with more recent
data linking brain insulin/IGF-1 function to the etiology of a
number of neurodegenerative diseases will, undoubtedly,
translate into more clinically-oriented avenues of research
in the near future. As exempliﬁed above, anti-diabetic
drugs seem to improve symptoms associated with AD and,
probably, other nervous system pathologies (though not in
every patient). It is expected that future studies will take
advantage of postgenomic technologies in order to generate
molecular and/or biochemical signatures aimed at identify-
ing patients who may beneﬁt from these therapies. Finally,
H. Werner, D. LeRoith1952biomarkers identiﬁcation may help evaluate the risk of
diabetes patients to develop AD.
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